Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DYN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsFDA accepts Dyne's DMD treatment BLA, grants Priority Review with Jan 2027 target date
Filed July 20, 2026 · Period ending July 20, 2026 · ~1 min read
Key Changes
-
high
FDA accepted BLA for zeleciment rostudirsen (DMD exon 51 skipping treatment), granted Priority Review with Jan 21, 2027 target action date
Item 8.01 verify on EDGAR → -
high
Company expects potential U.S. launch in Q1 2027, assuming approval on anticipated timeline
Item 8.01 verify on EDGAR →
Summary
Dyne Therapeutics disclosed that the FDA has accepted its biologics license application for zeleciment rostudirsen, a treatment for Duchenne muscular dystrophy patients amenable to exon 51 skipping, and granted Priority Review. The agency assigned a target action date of January 21, 2027 under the Prescription Drug User Fee Act. This marks a critical regulatory milestone for Dyne's lead product candidate as it moves toward potential commercialization.
Priority Review shortens the FDA's review timeline from the standard ten months to six months, reflecting the agency's assessment that the therapy addresses an unmet medical need. The company expects to launch commercially in the U.S. during the first quarter of 2027 if approval is received on schedule, representing Dyne's transition from clinical-stage to commercial operations. Retail holders should watch for the FDA's decision by the January 2027 target date.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the U.S. Food and Drug Administration (“FDA”) has accepted for review its biologics license application (“BLA”) for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for the treatment of individuals with Duchenne muscular dystrophy (“DMD”) amenable to exon 51 skipping. The FDA has granted the BLA Priority Review and assigned a Prescription Drug User Fee Act target action date of January 21, 2027.
The FDA accepted Dyne's biologics license application for zeleciment rostudirsen, a treatment for Duchenne muscular dystrophy patients amenable to exon 51 skipping. Priority Review designation accelerates the review timeline, with a target decision date of January 21, 2027. This is the company's lead product candidate moving toward potential commercialization.
Added in current filing · verify on EDGAR →
The Company continues to expect a potential U.S. launch of z-rostudirsen in the first quarter of 2027, assuming approval is received on the anticipated timeline.
Dyne expects to launch zeleciment rostudirsen commercially in the U.S. during the first quarter of 2027, contingent on receiving FDA approval by the January 2027 target date. This represents the company's transition from a clinical-stage to a commercial-stage biopharmaceutical company.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 23, 2026 · How we verify